GE HealthCare shares have surged nearly 27% since October 2023, driven by AI-driven strategies and innovation in healthcare diagnostics, despite some volatility in revenue growth. The bullish outlook for 2025 is supported by GEHC's AI advancements, expected sales and profitability improvements, and a significant backlog of $19.6 billion. AI-driven healthcare solutions are projected to enhance d...
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehe...
GE HealthCare Technologies is rated a buy due to strong growth prospects, a healthy backlog, and favorable valuation compared to peers. The company's revenue growth is supported by new product innovations, including the FDA-approved Flyrcado, and potential recovery in Chinese demand. Margins are expected to improve through cost optimization, volume leverage, and strategic pricing, with a medium...
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep learning image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America (RSNA) 2024 Annual Meeting, in Chicago, IL. Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of b...
CHICAGO--(BUSINESS WIRE)--As part of a companywide commitment to advance innovation that improves the health of patients and the planet, GE HealthCare (Nasdaq: GEHC) is highlighting several solutions with increased focus on sustainability at the Radiological Society of North America (RSNA) 2024 Annual Meeting, which is held Dec. 1-4 in Chicago, IL. “With a deep appreciation for the importance o...
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today the 510(k) submission to the U.S. Food and Drug Administration for CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clear...
CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare to acquire remaining 50% stake in Nihon Medi-Physics (NMP), a leading radiopharmaceutical company in Japan, from Sumitomo Chemical.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially laun...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.